<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="1981">
  <stage>Registered</stage>
  <submitdate>30/08/2007</submitdate>
  <approvaldate>30/08/2007</approvaldate>
  <nctid>NCT00683696</nctid>
  <trial_identification>
    <studytitle>Echocardiography Guided Cardiac Resynchronization Therapy (EchoCRT)</studytitle>
    <scientifictitle>Echocardiography Guided Cardiac Resynchronization Therapy (EchoCRT)</scientifictitle>
    <utrn />
    <trialacronym>EchoCRT</trialacronym>
    <secondaryid>EchoCRT</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Heart Failure</healthcondition>
    <healthcondition>Ventricular Dyssynchrony</healthcondition>
    <conditioncode>
      <conditioncode1>Cardiovascular </conditioncode1>
      <conditioncode2>Coronary heart disease</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cardiovascular </conditioncode1>
      <conditioncode2>Other cardiovascular diseases</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: devices - Implantable Cardioverter Defibrillator with Cardiac Resynchronization Therapy (BIOTRONIK Lumax HF-T CRT-D)

Experimental: CRT=ON - Cardiac Resynchronization Therapy activated.

Active Comparator: CRT=OFF - Cardiac Resynchronization Therapy deactivated.


Treatment: devices: Implantable Cardioverter Defibrillator with Cardiac Resynchronization Therapy (BIOTRONIK Lumax HF-T CRT-D)
All patients will receive a commercially available BIOTRONIK Lumax HF-T CRT-D system with ICD back-up enabled. Patients will be randomized to CRT=ON or CRT=OFF.

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: devices</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Composite Primary Endpoint: Number of Subjects With First Hospitalization for Worsening Heart Failure or Death - The primary efficacy endpoint will evaluate the effect of CRT=ON versus CRT=OFF in time to event of a combined endpoint of all-cause mortality or first hospitalization for worsening heart failure.</outcome>
      <timepoint>From date of randomization until date of death from any cause or date of first hospitalization for worsening heart failure, whichever came first, assessed up to date of study exit, with a mean treatment duration of 1.6 years</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Number of Subjects That Underwent Implant Attempt Without System- or Implant-Related Complications (Complication-Free) - The primary safety endpoint will evaluate the complication-free rate of the Lumax HF-T CRT-D devices in the narrow QRS subject population.</outcome>
      <timepoint>6 months</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Rate of Worsening Heart Failure Hospitalization (Hospitalizations Per Subject-year) - Evaluate the effects of CRT=ON compared to CRT=OFF on the rate of hospitalization for worsening heart failure (WHF).</outcome>
      <timepoint>Study duration from randomization to study exit</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>NYHA Classification Change - Evaluate the effects of CRT=ON compared to CRT=OFF in relation to the change in NYHA classification.</outcome>
      <timepoint>6 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change in Quality of Life Scores From Baseline to 6-Month Follow-up - Evaluate the effects of CRT=ON compared to CRT=OFF in relation to the change in the Minnesota Living with Heart Failure (MLHF) Quality of Life (QOL) Questionnaire.</outcome>
      <timepoint>6 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Composite Score of Death, Hospitalization for Worsening Heart Failure and Change in Quality of Life - Evaluate the effects of CRT=ON compared to CRT=OFF in relation to a composite endpoint of all-cause mortality, hospitalization for worsening heart failure and change in the MLHF Quality of Life Questionnaire.</outcome>
      <timepoint>Study duration from randomization to study exit for death, 24 months for hospitalization, 6 months for QOL evaluation</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Number of Subjects With All-cause Mortality - Evaluate the all-cause mortality rate between the CRT=ON compared to CRT=OFF group.</outcome>
      <timepoint>Study duration from randomization to study exit</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Men and women 18 years of age or older.

          -  Understand the nature of the procedure.

          -  Give written informed consent.

          -  Willing and able to complete all testing required by the clinical protocol.

          -  Indication for an implantable cardioverter defibrillator (ICD).

          -  NYHA class III-IV within the last three months prior to enrollment and at baseline (at
             baseline only: also Stage C according to ACC/AHA guidelines).

          -  Stable optimal pharmacologic therapy for HF.

          -  An ejection fraction = 35% within one year prior to enrollment and confirmed on the
             baseline echocardiogram.

          -  Increased left ventricular dimension, defined as LVEDD = 55 mm.

          -  Resting QRS duration &lt; 130 ms evidenced by a historical 12-lead ECG prior to
             enrollment and at baseline.

          -  Ventricular dyssynchrony assessed by echocardiography locally and confirmed by the
             echo core lab. One of the two following criteria has to be present to include the
             subject in the study:

               -  Intra-left ventricular dyssynchrony measured by color Tissue Doppler Imaging
                  (TDI) with an opposing wall delay of = 80 ms in the 4-chamber or apical long-axis
                  view.

               -  Speckle-tracking radial strain septal-posterior wall delay = 130 ms.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Implanted pacemaker or defibrillator with &gt;10% ventricular pacing, as demonstrated by
             device statistics averaged over at least the last three months prior to enrollment.

          -  Women who are pregnant, lactating, or planning to become pregnant during the course of
             the trial.

          -  Bradycardia pacing indication.

          -  Surgically correctable primary valvular heart disease, i.e. aortic stenosis, torn
             cordae, or flail segment.

          -  Coronary artery bypass graft surgery or percutaneous coronary intervention (balloon
             and/or stent angioplasty) within the past 3 months prior to enrollment.

          -  Enzyme-positive myocardial infarction within the past 3 months prior to enrollment.

          -  Angiographic evidence of coronary disease, candidates for coronary revascularization
             likely to undergo coronary artery bypass graft surgery or percutaneous coronary
             intervention in the next 3 months.

          -  Irreversible brain damage from preexisting cerebral disease.

          -  Reversible non-ischemic cardiomyopathy such as acute viral myocarditis.

          -  Permanent second or third degree heart block.

          -  Chagas disease.

          -  Persistent or paroxysmal atrial fibrillation within one month prior to enrollment.

          -  Expected to receive heart transplantation within six months.

          -  Current inotropic therapy.

          -  Acutely decompensated heart failure.

          -  Contrast dye allergy and unable or unwilling to undergo pretreatment with steroids
             and/or diphenhydramine.

          -  Life expectancy of less than six months.

          -  Presence of any disease, other than the subject's cardiac disease associated with a
             reduced likelihood of survival for the duration of the trial, (e.g. cancer).

          -  Significant renal insufficiency defined as a serum creatinine &gt; 2.5 mg/dL (&gt; 221
             µmol/L) within the last four weeks prior to enrollment..

          -  Liver failure, defined as three times the upper limit of normal for aminotransferases.

          -  Participation in any other clinical trial.

          -  Unable to return for follow-up visits due to distance from the clinic.

          -  Do not anticipate being a resident of the area for the scheduled duration of the
             trial.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2 />
    <masking3>The people assessing the outcomes</masking3>
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2/Phase 3</phase>
    <anticipatedstartdate />
    <actualstartdate>1/08/2008</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>1680</actualsamplesize>
    <recruitmentstatus>Terminated</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/03/2013</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <hospital>Flinders Medical Center Adelaide - Adelaide</hospital>
    <hospital>Princess Alexandra Hospital - Brisbane</hospital>
    <hospital>St. Vincent's Hospital - Melbourne</hospital>
    <hospital>Sir Charles Gairdner Hospital - Nedland</hospital>
    <hospital>Royal Perth Hospital - Perth</hospital>
    <postcode> - Adelaide</postcode>
    <postcode> - Brisbane</postcode>
    <postcode> - Melbourne</postcode>
    <postcode> - Nedland</postcode>
    <postcode> - Perth</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Connecticut</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Florida</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Georgia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Illinois</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Indiana</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Kentucky</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Massachusetts</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Michigan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Minnesota</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Mississippi</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Missouri</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New Jersey</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New York</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>North Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Ohio</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Oregon</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Pennsylvania</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>South Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Tennessee</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Virginia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Washington</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Wisconsin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Austria</country>
      <state>Graz</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Aalst</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Brussels</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Ontario</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Edmonton</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czech Republic</country>
      <state>Olomouc</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czech Republic</country>
      <state>Prague</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Denmark</country>
      <state>Aalborg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Denmark</country>
      <state>Aarhus</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Denmark</country>
      <state>Copenhagen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Denmark</country>
      <state>Hellerup</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Nantes</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Rennes</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Rouen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Bad Oeynhausen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Berlin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Bernau</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Essen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Hamburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Jena</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Leipzig</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Lunen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Lüdenscheid</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Magdeburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state>Ashkelon</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state>Beer Sheva</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state>Jerusalem</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state>Tel Aviv</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state>Tel Hashomer</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Bari</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Brescia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Naples</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Novara</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Amsterdam</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Leiden</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Warsaw</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Wroclaw</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Portugal</country>
      <state>Lisbon</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Alicante</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Barcelona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Switzerland</country>
      <state>Geneve</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Switzerland</country>
      <state>Lausanne</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Switzerland</country>
      <state>Zurich</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Coventry</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Leicester</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>London</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>West Midlands</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Biotronik, Inc.</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>University of Zurich</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The EchoCRT trial evaluates the effects of Cardiac Resynchronization Therapy (CRT) on
      mortality and morbidity of subjects with heart failure due to left ventricular systolic
      dysfunction, already receiving optimized HF medication, with a narrow QRS width (&lt; 130 ms)
      and echocardiographic evidence of ventricular dyssynchrony.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00683696</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Frank Ruschitzka, MD</name>
      <address>University of Zurich, Switzerland</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>